AWS
CORT icon

Atria Wealth Solutions’s Corcept Therapeutics CORT Stock Holding History

Atria Wealth Solutions’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,610
Closed -$410K – 1945
2024
Q2 		$410K Sell
12,610
-1,248
-9% -$34.2K ﹤0.01% 1331
2024
Q1 		$349K Buy
+13,858
New +$327K ﹤0.01% 1464
2023
Q2 		– Sell
-19,706
Closed -$427K – 1890
2023
Q1 		$427K Buy
+19,706
New +$432K 0.01% 1216

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Atria Wealth Solutions's CORT Position: Q3 2024 in Review

Atria Wealth Solutions sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 12,610 shares — an estimated $410K sold.

Atria Wealth Solutions first reported a position in CORT in Q1 2023 and held it in 3 quarters. The position peaked at $427K in Q1 2023. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Atria Wealth Solutions reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 12,610 Corcept Therapeutics shares in Q3 2024, an estimated $410K.
  • Atria Wealth Solutions first reported a position in Corcept Therapeutics in Q1 2023 and held it in 3 quarters.
  • Atria Wealth Solutions's Corcept Therapeutics position peaked at $427K in Q1 2023.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Atria Wealth Solutions's 13F filing for Q3 2024, filed 8 Nov 2024.